Gastric equivalent of the ‘Holy Plane’ to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson’s historic schema Hisashi ShinoharaYasunori KurahashiYoshinori Ishida Review Article 02 January 2021 Pages: 273 - 282
Gastric cancer is highly prevalent in Lynch syndrome patients with atrophic gastritis Hourin ChoMasayoshi YamadaKokichi Sugano Original Article 13 August 2020 Pages: 283 - 291
The potential role of nontyphoidal salmonellosis in gastric cancer: a nationwide matched cohort study Renin ChangJames Cheng-Chung WeiYao-Min Hung Original Article 01 November 2020 Pages: 292 - 301
Promising aberrant DNA methylation marker to predict gastric cancer development in individuals with family history and long-term effects of H. pylori eradication on DNA methylation Hee Jin KimNayoung KimDong Ho Lee Original Article 11 September 2020 Pages: 302 - 313
Tumor suppressor ATP4B serve as a promising biomarker for worsening of gastric atrophy and poor differentiation Yuanming PanXin WangJianqiu Sheng Original Article 27 October 2020 Pages: 314 - 326
Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer So-Woon KimJin RohChan-Sik Park Original Article 14 September 2020 Pages: 327 - 340
MAGEA10 expression is a predictive marker of early hepatic recurrence after curative gastrectomy for gastric and gastroesophageal junction cancer Keiichi FujiyaMasanori TerashimaKen Yamaguchi Original Article 23 September 2020 Pages: 341 - 351
Apatinib exhibits synergistic effect with pyrotinib and reverses acquired pyrotinib resistance in HER2-positive gastric cancer via stem cell factor/c-kit signaling and its downstream pathways Beibei SuTingting HuangXianglin Yuan Original Article Open access 08 October 2020 Pages: 352 - 367
Histological diversity and molecular characteristics in gastric cancer: relation of cancer stem cell-related molecules and receptor tyrosine kinase molecules to mixed histological type and more histological patterns Kazuhiro SentaniTakeharu ImaiWataru Yasui Original Article 28 October 2020 Pages: 368 - 381
Molecular alterations in gastric cancer and the surrounding intestinal metaplastic mucosa: an analysis of isolated glands Ryo SugimotoWataru HabanoTamotsu Sugai Original Article 03 November 2020 Pages: 382 - 391
Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosis Chiara MolinariGianluca TedaldiLuca Saragoni Original Article 06 November 2020 Pages: 392 - 401
SHARPIN stabilizes β-catenin through a linear ubiquitination-independent manner to support gastric tumorigenesis Liang ZhangQin LiuBin Wang Original Article 07 November 2020 Pages: 402 - 416
Diagnostic performance in gastric cancer is higher using endocytoscopy with narrow-band imaging than using magnifying endoscopy with narrow-band imaging Yusuke HoriuchiToshiaki HirasawaJunko Fujisaki Original Article 03 October 2020 Pages: 417 - 427
Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3) Yukinori KurokawaJin MatsuyamaTaroh Satoh Original Article 10 August 2020 Pages: 428 - 434
Clinical outcomes of endoscopic resection for undifferentiated intramucosal early gastric cancer larger than 2 cm Hyo-Joon YangSu Youn NamIl Ju Choi Original Article 24 August 2020 Pages: 435 - 444
External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? Paula Jimenez-FonsecaAlberto Carmona-BayonasJavier Gallego Original Article Open access 24 September 2020 Pages: 445 - 456
Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors Yeun-Yoon KimJeeyun LeeDongil Choi Original Article 24 September 2020 Pages: 457 - 466
Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial Kazumasa FujitaniKohei ShitaraWasaburo Koizumi Original Article Open access 02 November 2020 Pages: 467 - 476
Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial Kazumasa FujitaniKohei ShitaraWasaburo Koizumi Correction Open access 09 December 2020 Pages: 477 - 478
A nonrandomized, single-arm confirmatory trial of expanded endoscopic submucosal dissection indication for undifferentiated early gastric cancer: Japan Clinical Oncology Group study (JCOG1009/1010) Kohei TakizawaHiroyuki Onothe Gastrointestinal Endoscopy Group (GIESG) and the Stomach Cancer Study Group (SCSG) of Japan Clinical Oncology Group Original Article 08 November 2020 Pages: 479 - 491
Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial Yoshiaki IwasakiMasanori TerashimaMitsuru Sasako Original Article 16 November 2020 Pages: 492 - 502
Multi-institutional development and validation of a nomogram to predict recurrence after curative resection of gastric neuroendocrine/mixed adenoneuroendocrine carcinoma Hualong ZhengYaJun ZhaoChangming Huang Original Article 11 September 2020 Pages: 503 - 514
Assessment of diagnostic value of fluorescent lymphography-guided lymphadenectomy for gastric cancer Minoa K. JungMinah ChoWoo Jin Hyung Original Article 18 September 2020 Pages: 515 - 525
Association of surgeon and hospital volume with postoperative mortality after total gastrectomy for gastric cancer: data from 71,307 Japanese patients collected from a nationwide web-based data entry system Masaaki IwatsukiHiroyuki YamamotoHideo Baba Original Article 09 October 2020 Pages: 526 - 534
Multicenter prospective trial of total gastrectomy versus proximal gastrectomy for upper third cT1 gastric cancer Makoto YamasakiS. TakiguchiY. Doki Original Article 29 October 2020 Pages: 535 - 543
